Marka R. Crittenden

Rindopepimut with temozolomide for patients with newly diagnosed, EGFRvIII-expressing glioblastoma (ACT IV): a randomised, double-blind, international phase 3 trial

Michael Weller, Nicholas Butowski, David Tran et al. · The Lancet Oncology · 2017 · 1.1K citations

Egfrviii-expressing Glioblastoma, Neuro-oncology, Act Iv +10

Optimizing Timing of Immunotherapy Improves Control of Tumors by Hypofractionated Radiation Therapy

Kristina H. Young, Jason R. Baird, Talicia Savage et al. · PLoS ONE · 2016 · 308 citations · Full text

Immunology, Ideal Timing, Immunotherapy +17

Phase 1 Study of Stereotactic Body Radiotherapy and Interleukin-2—Tumor and Immunological Responses

Steven K. Seung, Brendan D. Curti, Marka R. Crittenden et al. · Science Translational Medicine · 2012 · 302 citations

Radiotherapy Combined with Novel STING-Targeting Oligonucleotides Results in Regression of Established Tumors

Jason R. Baird, David J. Friedman, Benjamin Cottam et al. · Cancer Research · 2015 · 232 citations

Immunology, Immune Regulation, Pathology +24

TGFβ suppresses CD8+ T cell expression of CXCR3 and tumor trafficking

Andrew J. Gunderson, Tomoko Yamazaki, Kayla McCarty et al. · Nature Communications · 2020 · 204 citations · Full text